Harvard Bioscience Future Growth
Future criteria checks 3/6
Harvard Bioscience is forecast to grow earnings and revenue by 98.9% and 7.2% per annum respectively. EPS is expected to grow by 99.1% per annum. Return on equity is forecast to be 7.8% in 3 years.
Key information
98.9%
Earnings growth rate
99.1%
EPS growth rate
Life Sciences earnings growth | 17.4% |
Revenue growth rate | 7.2% |
Future return on equity | 7.8% |
Analyst coverage | Low |
Last updated | 08 Mar 2024 |
Recent future growth updates
Recent updates
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?
Nov 26Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 140 | 8 | 14 | 18 | 1 |
12/31/2025 | 126 | 3 | 11 | 15 | 2 |
12/31/2024 | 114 | 0 | 8 | 11 | 2 |
12/31/2023 | 112 | -3 | 12 | 14 | N/A |
9/30/2023 | 113 | -3 | 11 | 12 | N/A |
6/30/2023 | 114 | -5 | 7 | 9 | N/A |
3/31/2023 | 115 | -2 | 4 | 5 | N/A |
12/31/2022 | 113 | -10 | 0 | 1 | N/A |
9/30/2022 | 118 | -7 | -3 | -1 | N/A |
6/30/2022 | 121 | -4 | -4 | -3 | N/A |
3/31/2022 | 121 | -6 | -3 | -2 | N/A |
12/31/2021 | 119 | 0 | 0 | 1 | N/A |
9/30/2021 | 117 | -2 | 2 | 4 | N/A |
6/30/2021 | 111 | -3 | 5 | 6 | N/A |
3/31/2021 | 105 | -4 | 6 | 7 | N/A |
12/31/2020 | 102 | -8 | 8 | 9 | N/A |
9/30/2020 | 102 | -7 | 8 | 9 | N/A |
6/30/2020 | 105 | -8 | 9 | 11 | N/A |
3/31/2020 | 112 | -7 | 8 | 9 | N/A |
12/31/2019 | 116 | -5 | 7 | 8 | N/A |
9/30/2019 | 119 | -2 | 8 | 8 | N/A |
6/30/2019 | 120 | 0 | 3 | 4 | N/A |
3/31/2019 | 122 | -1 | 4 | 4 | N/A |
12/31/2018 | 121 | -4 | 2 | 3 | N/A |
9/30/2018 | 109 | -8 | -2 | -1 | N/A |
6/30/2018 | 99 | -8 | 2 | 3 | N/A |
3/31/2018 | 86 | -7 | 1 | 2 | N/A |
12/31/2017 | 77 | -2 | 0 | 1 | N/A |
9/30/2017 | 82 | -3 | N/A | 4 | N/A |
6/30/2017 | 88 | -4 | N/A | 5 | N/A |
3/31/2017 | 96 | -4 | N/A | 5 | N/A |
12/31/2016 | 105 | -4 | N/A | 5 | N/A |
9/30/2016 | 106 | -20 | N/A | 5 | N/A |
6/30/2016 | 107 | -19 | N/A | 2 | N/A |
3/31/2016 | 110 | -18 | N/A | 0 | N/A |
12/31/2015 | 109 | -19 | N/A | 1 | N/A |
9/30/2015 | 111 | -2 | N/A | 0 | N/A |
6/30/2015 | 110 | 0 | N/A | 1 | N/A |
3/31/2015 | 109 | 0 | N/A | 3 | N/A |
12/31/2014 | 109 | 2 | N/A | 4 | N/A |
9/30/2014 | 106 | 2 | N/A | 4 | N/A |
6/30/2014 | 106 | 1 | N/A | 5 | N/A |
3/31/2014 | 105 | 1 | N/A | 5 | N/A |
12/31/2013 | 105 | 1 | N/A | 4 | N/A |
9/30/2013 | 106 | 4 | N/A | 4 | N/A |
6/30/2013 | 107 | 4 | N/A | 5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: HBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HBIO is expected to become profitable in the next 3 years.
Revenue vs Market: HBIO's revenue (7.2% per year) is forecast to grow slower than the US market (8.2% per year).
High Growth Revenue: HBIO's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HBIO's Return on Equity is forecast to be low in 3 years time (7.8%).